HilleVax to Participate in November Investor Conferences

Rhea-AI Summary

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, a clinical-stage biopharmaceutical company, will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day and the Stifel Healthcare Conference. Key discussions will focus on HIL-214, an investigational virus-like particle vaccine aimed at preventing moderate-to-severe norovirus-related gastroenteritis, and its ongoing Phase 2b clinical trial, NEST-IN1. Events are scheduled for November 14 and November 16, 2022, featuring CEO Robert Hershberg.

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the Guggenheim Securities 4^th Annual Immunology and Neurology Day and the Stifel Healthcare Conference. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b clinical trial NEST-IN1 will be topics of discussion at both events.

Guggenheim fireside chat details:
Date: Time: Moderator: HilleVax Participant:		Monday, November 14, 2022 3:55 – 4:20 p.m. Eastern Daylight Time (EDT) Seamus Fernandez Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer
Please contact your Guggenheim representative to access the session
Stifel presentation details: Date:                       Time:                       Moderator:                 HilleVax Participant:  Webcast Link:		Wednesday, November 16, 2022 8:35 – 9:05 a.m. Eastern Daylight Time (EDT) Stephen Willey Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer https://wsw.com/webcast/stifel74/hlvx/2126052

About HilleVax

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Contact:

Shane Maltbie
IR@hillevax.com
+1-617-213-5054

FAQ

What conferences will HilleVax participate in November 2022?

HilleVax will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day on November 14 and the Stifel Healthcare Conference on November 16, 2022.

What is HIL-214 and its significance?

HIL-214 is an investigational virus-like particle vaccine developed by HilleVax to prevent moderate-to-severe norovirus-related gastroenteritis.

What is the focus of HilleVax's ongoing clinical trial NEST-IN1?

The NEST-IN1 clinical trial focuses on evaluating HIL-214 for preventing norovirus-related acute gastroenteritis.

Who is presenting for HilleVax at the upcoming conferences?

Robert Hershberg, M.D., Ph.D., Chairman and CEO of HilleVax, will present at both conferences.

When is HilleVax's presentation at the Stifel Healthcare Conference?

HilleVax's presentation at the Stifel Healthcare Conference is scheduled for November 16, 2022, from 8:35 to 9:05 a.m. EDT.